Class summary at a glance.

Every drug in the Tricyclic Antidepressant class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 7tracked in Part D
CY24 Part D spend: $247.4Mcombined across class
Total Rx claims: 10.1M2.8M unique beneficiaries
Generic mfrs (active): 67across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Doxepin

Brand: Doxepin · 1.9M Part D claims (CY24) · 521K beneficiaries · First FDA approval: 1986-05-13

25 generic mfrs 665 plans require PA

Low NADAC$0.078

→

Avg plan cost$0.539

Part D spend $99.4M 7× spread, current vs floor

Class share

40%

of class CY24 spend

View profile →

Amitriptyline

5.7M Part D claims (CY24) · 1.5M beneficiaries · First FDA approval: 1977-11-21

10 generic mfrs 576 plans require PA

Low NADAC$0.035

→

Avg plan cost$0.102

Part D spend $82.0M 3× spread, current vs floor

Class share

33%

of class CY24 spend

View profile →

Nortriptyline

Brand: PAMELOR · 1.9M Part D claims (CY24) · 560K beneficiaries · First FDA approval: 1977-08-01

5 generic mfrs 40 plans require PA Discontinued

Low NADAC$0.123

→

Avg plan cost$0.181

Part D spend $31.8M 1× spread, current vs floor

Class share

13%

of class CY24 spend

View profile →

Clomipramine

Brand: ANAFRANIL · 189K Part D claims (CY24) · 31K beneficiaries · First FDA approval: 1989-12-29

13 generic mfrs 312 plans require PA

Low NADAC$0.203

→

Avg plan cost$0.234

Part D spend $22.2M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Imipramine

301K Part D claims (CY24) · 76K beneficiaries · First FDA approval: 2010-04-16

7 generic mfrs 143 plans require PA

Low NADAC$0.083

→

Avg plan cost$0.914

Part D spend $6.9M 11× spread, current vs floor

Class share

of class CY24 spend

View profile →

Desipramine

Brand: Desipramine Hydrochloride · 80K Part D claims (CY24) · 22K beneficiaries · First FDA approval: 1964-11-20

5 generic mfrs 462 plans require PA Discontinued

Low NADAC$0.146

→

Avg plan cost$0.325

Part D spend $4.9M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Amoxapine

3K Part D claims (CY24) · 746 beneficiaries · First FDA approval: 1991-06-28

2 generic mfrs 316 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $278639

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.